文献速递肝病消化道肿瘤与早癌

伴免疫细胞间质及EBV阳性肿瘤浸润淋巴细胞的肝细胞癌免疫基因组学特征

Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
PubMed 文献 · J Hepatol · 2019-03-29

研究纳入219例经典型肝细胞癌(C-HCC)与47例伴免疫细胞间质的肝细胞癌(HCC-IS),采用EBV原位杂交、免疫组化、多重免疫荧光及全外显子与转录组测序,比较基因组与预后参数。HCC-IS中CD8 T细胞浸润更常见、EBV阳性肿瘤浸润淋巴细胞更多、CTNNB1突变缺失,为无复发生存的独立有利因素;但EBV阳性TILs高密度亚组预后更差,并富集CD8 T细胞耗竭特征。

要点

  • HCC-IS中CD8 T细胞浸润比例及EBV阳性TILs比例均高于C-HCC。
  • HCC-IS中未见CTNNB1突变,C-HCC中为24.1%。
  • HCC-IS为无复发生存的独立有利因素,但EBV阳性TILs高密度亚组预后更差。

核心结论

  • HCC-IS是伴良好预后的独特肝细胞癌亚型,常伴EBV阳性TILs。
  • 肿瘤内EBV阳性TILs高密度与更差的复发和总生存相关,可能因CD8 T细胞耗竭导致免疫逃逸。
  • HCC-IS患者可能是免疫治疗的候选人群。

研究设计与样本

  • 研究纳入219例经典型肝细胞癌(C-HCC)和47例伴免疫细胞间质的肝细胞癌(HCC-IS)患者。
  • 采用EBV原位杂交、免疫组化、多重免疫荧光染色以及全外显子与转录组测序进行评估。
  • 从测序数据中提取人类白细胞抗原分型。
  • 比较HCC-IS与C-HCC的基因组和预后参数。

主要发现

  • HCC-IS中CD8 T细胞浸润较C-HCC更常见(平均每样本比例22.6% vs 8.9%,错误发现率q<0.001)。
  • CD20阳性肿瘤浸润淋巴细胞中EBV阳性率HCC-IS为74.5%,C-HCC为4.6%(p<0.001)。
  • CTNNB1突变在HCC-IS中未见,C-HCC中为24.1%(p=0.016)。
  • HCC-IS与EBV阳性C-HCC的抑制性和刺激性免疫调节因子表达水平相似。
  • 整体高甲基化、TILs中PD-1和PD-L1表达及肿瘤中PD-L1表达与HCC-IS相关(p<0.001),人类白细胞抗原型别与HCC类型或EBV阳性状态无关。

关键数值与推荐

  • CD8 T细胞平均每样本比例:HCC-IS 22.6% vs C-HCC 8.9%(q<0.001)。
  • CD20阳性TILs中EBV阳性率:HCC-IS 74.5% vs C-HCC 4.6%(p<0.001)。
  • CTNNB1突变率:HCC-IS 0% vs C-HCC 24.1%(p=0.016)。
  • 无复发生存:HCC-IS aHR 0.23(p=0.002);EBV阳性TILs高密度亚组 aHR 25.48(p<0.001)。
  • 总生存:EBV阳性TILs高密度亚组 aHR 9.6(p=0.003)。

临床怎么用

  • 原文结论指出HCC-IS患者可能是免疫治疗的候选人群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The immunogenomic characteristics of hepatocellular carcinomas (HCCs) with immune cell stroma (HCC-IS), defined histologically, have not been clarified. We investigated the clinical and molecular features of HCC-IS and the prognostic impact of Epstein-Barr virus (EBV) infection. METHODS: We evaluated 219 patients with conventional HCC (C-HCC) and 47 with HCC-IS using in situ hybridization for EBV, immunohistochemistry, multiplex immunofluorescence staining, and whole exome and transcriptome sequencing. Human leukocyte antigen types were also extracted from the sequencing data. Genomic and prognostic parameters were compared between HCC-IS and C-HCC. RESULTS: CD8 T cell infiltration was more frequent in HCC-IS than C-HCC (mean fraction/sample, 22.6% vs. 8.9%, false discovery rate q <0.001), as was EBV positivity in CD20-positive tumor-infiltrating lymphocytes (TILs) (74.5% vs. 4.6%, p <0.001). CTNNB1 mutations were not identified in any HCC-IS, while they were present in 24.1% of C-HCC (p = 0.016). Inhibitory and stimulatory immune modulators were expressed at similar levels in HCC-IS and EBV-positive C-HCC. Global hypermethylation, and expression of PD-1 and PD-L1 in TILs, and PD-L1 in tumors, were also associated with HCC-IS (p <0.001), whereas human leukocyte antigen type did not differ according to HCC type or EBV positivity. HCC-IS was an independent factor for favorable recurrence-free survival (adjusted hazard ratio [aHR] 0.23; p = 0.002). However, a subgroup of tumors with a high density of EBV-positive TILs had poorer recurrence-free (aHR 25.48; p <0.001) and overall (aHR 9.6; p = 0.003) survival, and significant enrichment of CD8 T cell exhaustion signatures (q = 0.0296). CONCLUSIONS: HCC-IS is a distinct HCC subtype associated with a good prognosis and frequent EBV-positive TILs. However, paradoxically, a high density of EBV-positive TILs in tumors is associated with inferior prognostic outcomes. Patients with HCC-IS could be candidates for immunotherapy. LAY SUMMARY: Hepatocellular carcinomas with histologic evidence of abundant immune cell infiltration are characterized by frequent activation of Epstein-Barr virus in tumor-infiltrating lymphocytes and less aggressive clinical behavior. However, a high density of Epstein-Barr virus-positive tumor-infiltrating lymphocytes is associated with inferior prognostic outcomes, possibly as a result of immune escape due to significant CD8 T cell exhaustion.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kang HJ, Oh JH, Chun SM, et al. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes. J Hepatol. 2019. PMID: 30930222. doi:10.1016/j.jhep.2019.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。